Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery

dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUNIMEP-Piracicaba
dc.date.accessioned2014-05-27T11:21:56Z
dc.date.available2014-05-27T11:21:56Z
dc.date.created2014-05-27T11:21:56Z
dc.date.issued2006-07-17
dc.identifierCurrent Drug Delivery, v. 3, n. 3, p. 275-285, 2006.
dc.identifier1567-2018
dc.identifierhttp://hdl.handle.net/11449/69006
dc.identifier10.2174/156720106777731019
dc.identifier2-s2.0-33745843605
dc.identifier5361569184579557
dc.identifier9129780536724256
dc.description.abstractThe use of the nasal route for drug delivery has attracted much interest in recent years in the pharmaceutical field. Local and principally systemic drug delivery can be achieved by this route of administration. But the nasal route of delivery is not applicable to all drugs. Polar drugs and some macromolecules are not absorbed in sufficient concentration due to poor membrane permeability, rapid clearance and enzymatic degradation into the nasal cavity. Thus, alternative means that help overcome these nasal barriers are currently in development. Absorption enhancers such as phospholipids and surfactants are constantly used, but care must be taken in relation to their concentration. Drug delivery systems including liposomes, cyclodextrins, micro- and nanoparticles are being investigated to increase the bioavailability of drugs delivered intranasally. This review article discusses recent progress and specific development issues relating to colloidal drug delivery systems in nasal drug delivery. © 2006 Bentham Science Publishers Ltd.
dc.languageeng
dc.relationCurrent Drug Delivery
dc.relation2.078
dc.relation0,443
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectColloidal drug delivery systems
dc.subjectNasal bioavailability
dc.subjectNasal delivery
dc.subjectantihistaminic agent
dc.subjectantimigraine agent
dc.subjectbarbital
dc.subjectbeclometasone
dc.subjectbeclometasone dipropionate
dc.subjectbudesonide
dc.subjectbuprenorphine
dc.subjectcefazolin
dc.subjectcorticosteroid derivative
dc.subjectcyclodextrin derivative
dc.subjectestradiol
dc.subjectflunisolide
dc.subjectfluticasone propionate
dc.subjectgentamicin
dc.subjectglyceryl trinitrate
dc.subjecthydralazine
dc.subjectinsulin
dc.subjectliposome
dc.subjectmetoprolol
dc.subjectmometasone furoate
dc.subjectnanoparticle
dc.subjectpenicillin G
dc.subjectpentobarbital
dc.subjectphenobarbital
dc.subjectphospholipid derivative
dc.subjectprogesterone
dc.subjectpropranolol
dc.subjectsurfactant
dc.subjecttestosterone
dc.subjecttriamcinolone acetonide
dc.subjectunindexed drug
dc.subjectbrain
dc.subjectcolloid
dc.subjectdrug absorption
dc.subjectdrug bioavailability
dc.subjectdrug clearance
dc.subjectdrug delivery system
dc.subjectdrug formulation
dc.subjectenzyme degradation
dc.subjecthuman
dc.subjectmacromolecule
dc.subjectmembrane permeability
dc.subjectnonhuman
dc.subjectnose cavity
dc.subjectpriority journal
dc.subjectreview
dc.subjectunspecified side effect
dc.subjectAdministration, Intranasal
dc.subjectAnimals
dc.subjectBiological Availability
dc.subjectColloids
dc.subjectDrug Carriers
dc.subjectDrug Delivery Systems
dc.subjectHumans
dc.subjectLiposomes
dc.subjectNanostructures
dc.subjectVaccines
dc.titleLiposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery
dc.typeOtros


Este ítem pertenece a la siguiente institución